ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BPRG Bioprogress

50.00
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioprogress LSE:BPRG London Ordinary Share GB0032681628 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 50.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Statement re. Share Price

17/08/2007 2:01pm

UK Regulatory


RNS Number:3595C
BioProgress PLC
17 August 2007


For Immediate Release                                             17 August 2007



                BioProgress plc ('BioProgress' or the 'Company')



                                 Trading update



London UK, 17th August 2007, the Board of BioProgress (AIM: BPRG), the specialty
pharmaceutical and healthcare company  has noted the recent fall in its share
price and whilst recognising the volatility in the UK stock market generally,
provides the following update.



Following the announcement on 28 June 2007 of the acquisition of Melbrosin,
BioProgress is pleased to announce that the integration of the new business is
progressing well.  The core products are performing to plan and cross
fertilisation of products into the other business units has commenced.



New product development and partner programmes remain on course to deliver to
the Company's expectations.



The Board is confident that the strategy put into place is being executed to
plan.  The Company remains on track to achieve market expectations for 2007.





For further information:


BioProgress Plc                                            + 44 (0) 20 7098 9881
Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO
Buchanan Communications                                    + 44 (0) 20 7466 5000
Rebecca Skye Dietrich

Mark Court





About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, the company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical and healthcare
products. The business continues to develop innovative delivery mechanisms using
its XGELTM polymer technology. For further information please go to
www.bioprogress.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

SPMPRMTTMMABBLR

1 Year Bioprogress Chart

1 Year Bioprogress Chart

1 Month Bioprogress Chart

1 Month Bioprogress Chart

Your Recent History

Delayed Upgrade Clock